Mark Danta

机构：UNSW Sydney, St Vincent's Hospital Sydney · ORCID：0000-0001-5551-6811

发表论文 136 篇 · 总被引 4601 次 · h-index 25

代表论文

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 516)
A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune disease (2025 · Immunity · 被引 22)
A potential novel treatment for cirrhosis‐related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease (2024 · British Journal of Clinical Pharmacology · 被引 13)
The Role of the Gastrointestinal Microbiome in Liver Disease (2023 · Pathogens · 被引 12)
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial (2025 · The Lancet. Gastroenterology & hepatology · 被引 11)
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS) (2023 · Journal of Hepatology · 被引 10)